Meta-analysis on modified Zuogui Pill combined with hormone in the treatment of premature ovarian failure

Abstract

Objective To evaluate the effectiveness and safety of modified Zuogui Pill combined with hormone in the treatment of premature ovarian failure (POF). Methods Randomized controlled trials were carried out by searching Chinese and English databases from the establishing to June, 2018. The methodological quality was assessed in the included randomized controlled trials. The treatment of premature ovarian failure by modified Zuogui Pill combined with hormone was systematically evaluated by RevMan 5.3 software. Results 11 randomized controlled trials involving 1 004 patients were included. Meta-analysis results showed that total effective rate (OR=4.44, 95% CI: 3.10-6.36, P<0.00001), Tranditional Chinese Medcine (TCM ) syndromes (including dizziness, tinnitus, hot flash night sweats, five upset fever, waist and knees), serum follicle stimulating hormone (FSH) level [standardised mean difference(SMD)=0.54, 95% CI: 0.13-0.95, P=0.01], luteinizing hormone (LH) level (SMD=0.90, 95% CI: 0.45-1.36, P<0.0001), estradiol (E2 )level (SMD=1.26, 95% CI: 0.12-2.40, P=0.03), endometrial thickness [weighted mean difference (WMD)=2.03, 95% CI: 0.07-3.99, P=0.04] improvement and the incidence of adverse reactions (OR=0.34, 95% CI: 0.12-0.95, P=0.04) in modified Zuogui Pill combined with hormone therapy were superior to those of pure hormone therapy. Conclusions The modified Zuogui Pill combined with hormone therapy shows better therapeutic effect and safety than hormone therapy on premature ovarian failure. Key words: Primary ovarian insufficiency; ZUOGUI PILL; Hormone replacement therapy; Meta-analysis